Market opportunity
Insufficient pharmacokinetics following administration of the hormone somatostatin has led to the synthesis of both peptide and non-peptide mimetics. Such drugs are used for the treatment of a range of conditions such as neuroendocrine tumors, acromegaly and increasingly, polycystic diseases of the liver and kidney. Treatments currently on the market including Sandostatin® (Novartis), with 2010 sales in the U.S. in excess of $1.2 billion*, and Somatuline® (Ipsen) are restricted in their requirement for parenteral administration.

Prof. Paul Murphy and his Research team at NUIG have recently identified the potential of using a benzomacrolactone scaffold to develop non-peptidal somatostatin mimetics, with excellent activity and suitable for oral delivery.

Stage of development
The value of this novel platform technology is protected by a patent application. Prototype benzomacrolactone compounds demonstrate superior activity to recently utilised sugar based-peptidomimetics. With development efforts ongoing, the Research Team is currently focused on improving compound affinity for somatostatin receptors, in addition to the optimising synthesis protocol.

Objective
We are interested in engaging with potential investors or collaborators with an interest in licensing or co-developing high potential technologies.

If you are interested in learning more about this opportunity please contact:

Dr. Seamus Coyne
Commercialisation Executive, Ignite Technology Transfer
National University of Ireland, Galway
seamus.coyne@nuigalway.ie
+353-91-495663
+353-87-6642604

* http://www.evaluatepharma.com